POS0061 (2024) INTERCEPTION OF THE DEVELOPMENT OF RA BY 1-YEAR MTX IN ACPA-NEGATIVE ARTHRALGIA PATIENTS AT INCREASED RISK FOR RA: 4 YEAR RESULTS OF THE TREAT EARLIER TRIAL MTX reduced development of RA in high risk acpa neg pts https://t.co/XWnzuVMlbn @RheumNow #EULAR2024

• EULAR Abstract Archive

T2T strategy in RA during pregnancy improves time to procreate Results PreCARA (T2T median DAS28CRP 2.33) vs. PARA median DAS28CRP 3.84) median TTP 84d vs. 196d TTP exceeded 12 months in 23% of PreCARA pts compared to 42% in the PARA pts. @RheumNow #EULAR2024 POS0436 https://t.co/DfgEvvtCwR

• https://twitter.com/AurelieRheumo/status/1801940518999388395/photo/1

EULAR Abstract Archive POS0894 (2024) SAFETY OF UPADACITINIB ACROSS RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS, AND AXIAL SPONDYLOARTHRITIS ENCOMPASSING 15,000 PATIENT-YEARS OF CLINICAL TRIAL DATA Reassuring 15000 pt yrs f/u RA PsA AS https://t.co/XWnzuVMlbn @RheumNow #EULAR2024

• EULAR Abstract Archive

Frank Buttgereit discusses potential reason for ceiling effect in RA and questions why we don’t use more combination therapy in RA (including low dose of of GC), using the example of Hypertension guidelines Is long term low dose GC in RA really a desirable option? @RheumNow… https://t.co/Nc7lldN7Nd https://t.co/63K96uuhKG

• https://twitter.com/i/web/status/1801927886011556002
• https://twitter.com/AurelieRheumo/status/1801927886011556002/photo/1
• https://twitter.com/AurelieRheumo/status/1801927886011556002/photo/1

#EULAR2024 POS0436 Another benefit of T2T to achieve remission by using less NSAIDs, lower GC, earlier use of SFZ, HCQ and TNF-i = shorter Time to Pregnancy from conception in #RA women (median 84 days) vs without pre-counselling & T2T (196 days) @RheumNow https://t.co/2ZpDLmPVt0

• https://twitter.com/Yuz6Yusof/status/1801926586620313822/photo/1

Data form TARA trial Taper in RA remission Flare free survival at 2 yrs 35% Risk of flare is similar in ACPA+ & ACPA- RA Risk of flare is similar if taper TNFi first or csDMARD first @RheumNow #EULAR2024 POS0405 https://t.co/89gAglHUcw

• https://twitter.com/AurelieRheumo/status/1801925729971569102/photo/1

#EULAR2024 @AilsaBosworth1 highlights the programmes available for pts diagnosed with #RA via the @NRAS_UK platform SMILE-RA and RightStart are great resources for self-management, can highly recommend to all clinicians! @RheumNow https://t.co/SgAMKkcycE

• https://twitter.com/DrMiniDey/status/1801922339904368984/photo/1
• https://twitter.com/DrMiniDey/status/1801922339904368984/photo/1

OP0238-HPR: effectiveness of digital patient education programme for RA self-management Intervention led to improved self-efficacy, w minor improved RA knowledge, #HealthLiteracy & #QoL ➡️such interventions may improve self-management & lower health costs @RheumNow #EULAR2024

The Role of Psychosocial Determinants in the Management of RA Dr. Mrinalini Dey reports from Eular 2024 in Vienna, Austria about an abstract she will present during the meeting, POS0309. https://t.co/o3vqHJnQHz https://t.co/ibMrNNCmUr

• The Role of Psychosocial Determinants in the Management of RA | RheumNow